nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.08.2012

The Clinical Relevance of the Clopidogrel–Proton Pump Inhibitor Interaction

verfasst von: Atif Mohammad, Emmanouil S. Brilakis, Rick A. Weideman, Bertis B. Little, Subhash Banerjee

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Proton pump inhibitors are often prescribed concomitantly with clopidogrel and aspirin to patients post-percutaneous coronary interventions and/or an acute coronary syndrome to mitigate the risk of potential gastrointestinal bleeding, associated primarily with clopidogrel use. Over the last several years, there have been data both supporting and refuting a clopidogrel–proton pump inhibitor interaction. This review critically considers the current evidence and provides practical recommendations to healthcare providers.

Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., & Casey, D. E., Jr. (2007). ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Journal of the American College of Cardiology, 50(7), e1–e157. Epub 2007/08/19.PubMedCrossRef

Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K., & Furberg, C. D. (2008). ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 118(18), 1894–1909. Epub 2008/10/07.PubMedCrossRef

Shuldiner, A. R., O'Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., & Horenstein, R. B. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA:The Journal of the American Medical Association, 302(8), 849–857. Epub 2009/08/27.PubMedCrossRef

Hulot, J. S., Bura, A., Villard, E., Azizi, M., Remones, V., & Goyenvalle, C. (2006). Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 108(7), 2244–2247. Epub 2006/06/15.PubMedCrossRef

Angiolillo, D. J., Gibson, C. M., Cheng, S., Ollier, C., Nicolas, O., & Bergougnan, L. (2011). Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clinical Pharmacology and Therapeutics, 89(1), 65–74. Epub 2010/09/17.PubMedCrossRef

O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., & Rozenman, Y. (2009). Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 374(9694), 989–997. Epub 2009/09/04.PubMedCrossRef

Bates, E. R., Lau, W. C., & Angiolillo, D. J. (2011). Clopidogrel–drug interactions. Journal of the American College of Cardiology, 57(11), 1251–1263. Epub 2011/03/12.PubMedCrossRef

Mega, J. L., Simon, T., Collet, J. P., Anderson, J. L., Antman, E. M., & Bliden, K. (2010). Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA: The Journal of the American Medical Association, 304(16), 1821–1830. doi:16. Epub 2010/10/28.CrossRef

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., & Brandt, J. T. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360(4), 354–362. Epub 2008/12/25.PubMedCrossRef

10.

Zhang, H., Ragueneau-Majlessi, I., & Levy, R. H. (2009). Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition. Drug Metabolism Letters, 3(4), 287–289. Epub 2009/12/10.PubMedCrossRef

11.

Sibbing, D., Morath, T., Stegherr, J., Braun, S., Vogt, W., & Hadamitzky, M. (2009). Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thrombosis and Haemostasis, 101(4), 714–719. Epub 2009/04/08.PubMed

12.

Neubauer, H., Engelhardt, A., Krueger, J. C., Lask, S., Boergel, J., Muegge, A., et al. (2010). Pantoprazole does not influence the antiplatelet effect of clopidogrel—A whole blood aggregometry study after coronary stenting. Journal of Cardiovascular Pharmacology, 56, 91–97.PubMedCrossRef

13.

Small, D. S., Farid, N. A., Payne, C. D., Weerakkody, G. J., Li, Y. G., & Brandt, J. T. (2008). Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Journal of Clinical Pharmacology, 48(4), 475–484. Epub 2008/02/28.PubMedCrossRef

14.

Gurbel, P. A., Tantry, U. S., & Shuldiner, A. R. (2010). Letter by Gurbel et al. regarding article, “Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement”. Circulation, 122(14), e478. author reply e9. Epub 2010/10/06.PubMedCrossRef

15.

Price, M. J., Tantry, U. S., & Gurbel, P. A. (2011). The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. Reviews in Cardiovascular Medicine, 12(1), 1–12. Epub 2011/05/07.PubMed

16.

Munoz-Torrero, J. F., Escudero, D., Suarez, C., Sanclemente, C., Pascual, M. T., & Zamorano, J. (2011). Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. Journal of Cardiovascular Pharmacology, 57(1), 13–19.PubMedCrossRef

17.

Charlot, M., Grove, E. L., Hansen, P. R., Olesen, J. B., Ahlehoff, O., Selmer, C., et al. (2011). Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ, 342, d2690.PubMedCrossRef

18.

Laine, L., & Hennekens, C. (2010). Proton pump inhibitor and clopidogrel interaction: fact or fiction? American Journal of Gastroenterology, 105(1), 34–41.PubMedCrossRef

19.

Simon, T., Steg, P. G., Gilard, M., Blanchard, D., Bonello, L., Hanssen, M., et al. (2011). Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation, 123(5), 474–482.PubMedCrossRef

20.

Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., & Tu, J. V. (2009). A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ: Canadian Medical Association Journal, 180(7), 713–718.PubMedCrossRef

21.

Ho, P. M., Maddox, T. M., Wang, L., Fihn, S. D., Jesse, R. L., Peterson, E. D., et al. (2009). Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA: The Journal of the American Medical Association, 301(9), 937–944.CrossRef

22.

Li, X. Q., Andersson, T. B., Ahlstrom, M., & Weidolf, L. (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metabolism and Disposition, 32(8), 821–827.PubMedCrossRef

23.

Stockl, K. M., Le, L., Zakharyan, A., Harada, A. S., Solow, B. K., Addiego, J. E., et al. (2010). Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Archives of Internal Medicine, 170(8), 704–710.PubMedCrossRef

24.

Kreutz, R. P., Stanek, E. J., Aubert, R., Yao, J., Breall, J. A., Desta, Z., et al. (2010). Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy, 30(8), 787–796.PubMedCrossRef

25.

Ray, W. A., Murray, K. T., Griffin, M. R., Chung, C. P., Smalley, W. E., Hall, K., et al. (2010). Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Annals of Internal Medicine, 152(6), 337–345.PubMed

26.

O'Donoghue, M., Antman, E. M., Braunwald, E., Murphy, S. A., Steg, P. G., Finkelstein, A., et al. (2009). The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology, 54(8), 678–685.PubMedCrossRef

27.

Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., et al. (2010). Clopidogrel with or without omeprazole in coronary artery disease. The New England Journal of Medicine, 363(20), 1909–1917.PubMedCrossRef

28.

Depta, J. P., & Bhatt, D. L. (2010). Omeprazole and clopidogrel: Should clinicians be worried? Cleveland Clinic Journal of Medicine, 77(2), 113–116.PubMedCrossRef

29.

Gurbel, P. A., & Tantry, U. S. (2011). Antiplatelet therapy: Clopidogrel–PPIs interaction, an ongoing controversy. Nature Reviews Cardiology, 8(1), 7–8.PubMedCrossRef

30.

Banerjee, S., Weideman, R. A., Weideman, M. W., Little, B. B., Kelly, K. C., Gunter, J. T., et al. (2011). Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. The American Journal of Cardiology, 107(6), 871–878.PubMedCrossRef

31.

Ferreiro, J. L., Ueno, M., Tomasello, S. D., Capodanno, D., Desai, B., Dharmashankar, K., et al. (2011). Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circulation. Cardiovascular Interventions, 4(3), 273–279.PubMedCrossRef

Titel: The Clinical Relevance of the Clopidogrel–Proton Pump Inhibitor Interaction
verfasst von: Atif Mohammad
Emmanouil S. Brilakis
Rick A. Weideman
Bertis B. Little
Subhash Banerjee
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 4/2012
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-011-9334-7

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Cardiovascular Disease Risk in Young People with Type 1 Diabetes

Erratum to: Routine Invasive Versus Conservative Management Strategies in Acute Coronary Syndrome: Time for a “Hybrid” Approach

Association Between Endothelial Nitric Oxide Synthase Polymorphisms and Atrial Fibrillation: A Meta-analysis

Erratum to: Cardiovascular Disease Risk in Young People with Type 1 Diabetes